Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.
Gulikers JL, Veerman GDM, Jebbink M, Kruithof PD, Steendam CMJ, Boosman RJ, Mathijssen RHJ, Tjan-Heijnen VCG, Driessen JHM, Dursun S, Smit EF, Dingemans AC, van Geel RMJM, Croes S, Hendriks LEL.
Gulikers JL, et al. Among authors: smit ef.
JTO Clin Res Rep. 2024 Feb 20;5(4):100656. doi: 10.1016/j.jtocrr.2024.100656. eCollection 2024 Apr.
JTO Clin Res Rep. 2024.
PMID: 38550297
Free PMC article.